OBJECTIVES: The aim of this study was to investigate the impact of cardiac resynchronization therapy (CRT) on right ventricular (RV) function and the influence of RV dysfunction on the echocardiographic and clinical response to CRT among patients enrolled in the CARE-HF (Cardiac Resynchronization-Heart Failure) trial. BACKGROUND:Cardiac resynchronization therapy prolongs survival in appropriately selected patients with heart failure but the benefit might be diminished in patients with RV dysfunction. METHODS: Of 813 patients enrolled in the CARE-HF study, 688 had tricuspid plane systolic excursion (TAPSE) measured at baseline, and 345 of these were assigned to CRT. Their median (interquartile range) age was 66 (58 to 71) years, left ventricular (LV) ejection fraction was 24% (21% to 28%), and TAPSE was 19 (16 to 22) mm. Baseline LV function and size and QRS duration were similar among TAPSE tertiles, but those in the worst tertile (TAPSE <17.4 mm) were more likely to have ischemic heart disease. RESULTS: Overall, CRT improved LV but not RV structure and function with little evidence of an interaction with TAPSE. During a median (interquartile range) follow-up of 748 (582 to 950) days, 213 deaths occurred. Patients with lower TAPSE had a higher mortality, regardless of assigned treatment (p < 0.001). Greater inter-ventricular mechanical delay, New York Heart Association functional class, mitral regurgitation, and N-terminal pro-B-type natriuretic peptide, lower TAPSE, and assignment to the control group were independently associated with higher mortality. Reduction in mortality with CRT was similar in each tertile of TAPSE. CONCLUSIONS: Right ventricular dysfunction is a powerful determinant of prognosis among candidates for CRT, regardless of treatment assigned, but did not diminish the prognostic benefits of CRT among patients enrolled in the CARE-HF trial. (Care-HF CArdiac Resynchronization in Heart Failure; NCT00170300).
RCT Entities:
OBJECTIVES: The aim of this study was to investigate the impact of cardiac resynchronization therapy (CRT) on right ventricular (RV) function and the influence of RV dysfunction on the echocardiographic and clinical response to CRT among patients enrolled in the CARE-HF (Cardiac Resynchronization-Heart Failure) trial. BACKGROUND: Cardiac resynchronization therapy prolongs survival in appropriately selected patients with heart failure but the benefit might be diminished in patients with RV dysfunction. METHODS: Of 813 patients enrolled in the CARE-HF study, 688 had tricuspid plane systolic excursion (TAPSE) measured at baseline, and 345 of these were assigned to CRT. Their median (interquartile range) age was 66 (58 to 71) years, left ventricular (LV) ejection fraction was 24% (21% to 28%), and TAPSE was 19 (16 to 22) mm. Baseline LV function and size and QRS duration were similar among TAPSE tertiles, but those in the worst tertile (TAPSE <17.4 mm) were more likely to have ischemic heart disease. RESULTS: Overall, CRT improved LV but not RV structure and function with little evidence of an interaction with TAPSE. During a median (interquartile range) follow-up of 748 (582 to 950) days, 213 deaths occurred. Patients with lower TAPSE had a higher mortality, regardless of assigned treatment (p < 0.001). Greater inter-ventricular mechanical delay, New York Heart Association functional class, mitral regurgitation, and N-terminal pro-B-type natriuretic peptide, lower TAPSE, and assignment to the control group were independently associated with higher mortality. Reduction in mortality with CRT was similar in each tertile of TAPSE. CONCLUSIONS: Right ventricular dysfunction is a powerful determinant of prognosis among candidates for CRT, regardless of treatment assigned, but did not diminish the prognostic benefits of CRT among patients enrolled in the CARE-HF trial. (Care-HF CArdiac Resynchronization in Heart Failure; NCT00170300).
Authors: Pierpaolo Pellicori; Anil C Joseph; Jufen Zhang; Elena Lukaschuk; Nasser Sherwi; Christos V Bourantas; Huan Loh; Andrew L Clark; John Gf Cleland Journal: Clin Res Cardiol Date: 2015-04-23 Impact factor: 5.460
Authors: Diego Medvedofsky; Karima Addetia; Jamie Hamilton; Javier Leon Jimenez; Roberto M Lang; Victor Mor-Avi Journal: Int J Cardiovasc Imaging Date: 2015-05-07 Impact factor: 2.357
Authors: Tayler A Buchan; Crizza Ching; Farid Foroutan; Abdullah Malik; Julian F Daza; Nicholas Ng Fat Hing; Reed Siemieniuk; Nathan Evaniew; Ani Orchanian-Cheff; Heather J Ross; Gordon Guyatt; Ana C Alba Journal: Heart Fail Rev Date: 2021-07-05 Impact factor: 4.214
Authors: Silvia Deaconu; Alexandru Deaconu; Alina Scarlatescu; Ioana Petre; Sebastian Onciul; Aura Vijiiac; Diana Zamfir; Gabriela Marascu; Corneliu Iorgulescu; Andrei Dan Radu; Stefan Bogdan; Radu Vatasescu Journal: J Clin Med Date: 2021-05-31 Impact factor: 4.241